X4 Pharmaceuticals (XFOR) News Today $4.12 -0.11 (-2.60%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$4.14 +0.01 (+0.36%) As of 07:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XFOR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period X4 Pharmaceuticals Announces Board Resignations and AppointmentsAugust 25, 2025 | msn.comBrookline Capital Management Comments on XFOR Q3 EarningsAugust 21, 2025 | americanbankingnews.comX4 Pharmaceuticals Grants Inducement Equity Awards to New Executive OfficersAugust 15, 2025 | quiverquant.comQX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 15, 2025 | globenewswire.comX4 Pharmaceuticals Closes $85M Private Placement DealAugust 14, 2025 | theglobeandmail.comX4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. WainwrightAugust 13, 2025 | msn.comX4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price TargetAugust 13, 2025 | msn.comX4 Pharmaceuticals Announces Closing of Upsized $85 Million Private PlacementAugust 13, 2025 | globenewswire.comX4 Pharmaceuticals announces $60M financing, management changesAugust 12, 2025 | msn.comX4 Pharmaceuticals Announces $60M Equity FinancingAugust 12, 2025 | msn.comX4 Pharmaceuticals secures $60M PIPE financingAugust 12, 2025 | msn.comX4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board LeadershipAugust 12, 2025 | globenewswire.comX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comX4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2, 2025 | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comX4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDAJune 10, 2025 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comX4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA CongressMay 16, 2025 | nasdaq.comX4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA CongressMay 14, 2025 | globenewswire.comX4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings ResultsMay 5, 2025 | marketbeat.comX4 Pharmaceuticals (NASDAQ:XFOR) Stock Price Expected to Rise, HC Wainwright Analyst SaysMay 4, 2025 | marketbeat.comX4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...May 2, 2025 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call TranscriptMay 2, 2025 | insidermonkey.comX4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 4.9% - Time to Sell?May 1, 2025 | marketbeat.comX4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | finance.yahoo.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | globenewswire.comX4 Pharmaceuticals Q1 2025 Earnings PreviewApril 30, 2025 | msn.comX4 Pharmaceuticals Analyst RatingsApril 30, 2025 | benzinga.comEarnings Preview For X4 PharmaceuticalsApril 30, 2025 | benzinga.comX4 Pharmaceuticals (NASDAQ:XFOR) Sets New 1-Year Low - Here's WhyApril 30, 2025 | marketbeat.comX4 Pharmaceuticals To Implement 1-for-30 Reverse Stock Split On April 28April 26, 2025 | nasdaq.comX4 Pharmaceuticals trading halted, news pendingApril 26, 2025 | markets.businessinsider.comX4 Pharmaceuticals announces 1-for-30 reverse stock splitApril 25, 2025 | markets.businessinsider.comX4 Pharmaceuticals to conduct reverse stock splitApril 24, 2025 | msn.comX4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025April 24, 2025 | globenewswire.comX4 Pharmaceuticals Announces Reverse Stock SplitApril 24, 2025 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 23, 2025 | globenewswire.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comXFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25…March 27, 2025 | finance.yahoo.comBreaking Down X4 Pharmaceuticals: 4 Analysts Share Their ViewsMarch 27, 2025 | benzinga.comX4 Pharmaceuticals reports Q4 EPS (20c) vs. (10c) last yearMarch 26, 2025 | markets.businessinsider.comX4 Pharmaceuticals (NASDAQ:XFOR) Releases Earnings Results, Misses Estimates By $0.03 EPSMarch 26, 2025 | marketbeat.comX4 Pharmaceuticals outlines expected 2026 Phase 3 trial data release for mavorixaforMarch 25, 2025 | msn.comX4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | seekingalpha.comX4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | globenewswire.comX4 Pharmaceuticals Q4 2024 Earnings PreviewMarch 24, 2025 | msn.com Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XFOR Media Mentions By Week XFOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XFOR News Sentiment▼0.431.03▲Average Medical News Sentiment XFOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XFOR Articles This Week▼22▲XFOR Articles Average Week Get the Latest News and Ratings for XFOR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for X4 Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies IMRX News Today NVCT News Today ACTU News Today CRBU News Today CYBN News Today MCRB News Today NKTX News Today KYTX News Today BDTX News Today GLSI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XFOR) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access